Esiflo 250 Transcaps is a combination medication containing Salmeterol 50 mcg and Fluticasone Propionate 250 mcg, indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta2-adrenergic receptor agonist that provides sustained bronchodilation by relaxing airway smooth muscle, thereby improving airflow and reducing symptoms such as wheezing and shortness of breath. Fluticasone Propionate is a potent inhaled corticosteroid with anti-inflammatory properties that help decrease airway inflammation, reduce mucus production, and prevent exacerbations. The synergistic effect of these two active ingredients offers both rapid symptom relief and long-term control of airway inflammation. Esiflo 250 Transcaps is administered via inhalation, allowing targeted delivery to the lungs with minimal systemic absorption, thereby reducing the risk of systemic side effects. It is intended for regular use and is not suitable for the relief of acute bronchospasm. Patients should use this medication consistently as prescribed and consult their healthcare provider before discontinuation or if symptoms worsen. Common adverse effects may include oral candidiasis, hoarseness, and throat irritation, which can be minimized by rinsing the mouth after inhalation. Caution is advised in patients with cardiovascular disorders or hypersensitivity to any components.